Hyperbaric Oxygen for Aging: Does the Telomere Claim Hold Up?

Hyperbaric oxygen therapy (HBOT) has a longevity story built almost entirely on a single, genuinely surprising result. In 2020, an Israeli research group reported that a course of HBOT in healthy older adults lengthened immune-cell telomeres by about 20–38% and cut the share of senescent cells by roughly a third — two of the most cited cellular markers of aging, moving in the "younger" direction over just three months. That finding launched a wave of clinics selling HBOT as an anti-aging protocol. This page does what the marketing won't: it takes the study seriously, then weighs how much you should actually conclude from one small, unreplicated, expensive trial. For the wider map of what's earned its place versus what's hype, start with our pillar on longevity medicine: what's proven vs hyped.

What HBOT is

Hyperbaric oxygen therapy means breathing 100% oxygen inside a chamber pressurized above sea level — typically around 2 atmospheres absolute. The combination dramatically raises the amount of oxygen dissolved in your plasma and delivered to tissue. HBOT is an established, FDA-cleared treatment for a specific list of conditions: decompression sickness, carbon-monoxide poisoning, non-healing diabetic wounds, certain radiation injuries, and a handful of others. Its accepted mechanisms — promoting angiogenesis (new blood-vessel growth), mobilizing stem/progenitor cells, and modulating inflammation and oxidative-stress signaling — are real and reviewed in the clinical literature¹. The longevity question is entirely separate from those approved uses: it asks whether repeatedly dosing healthy people with hyperbaric oxygen can slow or reverse biological aging. That is not an approved indication, and the evidence for it is thin.

The headline study: telomeres and senescent cells

The paper that built the hype was Hachmo and colleagues, published in Aging in 2020². It enrolled 35 healthy adults aged 64 and older and gave them 60 daily HBOT sessions over three months, with no control group — each person served as their own baseline. The reported results were striking: telomere length in several immune-cell types increased by roughly 20–38%, and the proportion of senescent T-cells dropped by about 11–37% depending on the cell subset. In the authors' framing, HBOT had pushed two hallmark markers of cellular aging — telomere attrition and cellular senescence³ — backward.

A companion paper from the same group, using the same protocol, reported improvements in cognitive function in healthy older adults — gains in attention, processing speed, and executive function⁴. Together these two studies are essentially the entire human "HBOT for aging" evidence base, and both come from one team using one protocol in overlapping cohorts.

Why one striking study isn't proof

Take the telomere result at face value and it's remarkable. But several features should pull your confidence down hard before you spend thousands of dollars.

First, there was no control group. Telomere measurement is technically noisy, and an uncontrolled, unblinded design can't separate a true biological effect from measurement drift, regression to the mean, or expectation effects. Second, the sample was tiny — 35 people, with telomere effects reported in subsets of those. Third, and most important, it has not been independently replicated. A finding this consequential — "you can lengthen human telomeres with oxygen" — would normally be confirmed by other labs before it's treated as established. As of now, no independent group has reproduced it. Fourth, longer telomeres are not unambiguously good. Telomere length is a marker, not a goal in itself, and the relationship between lengthening telomeres and either lifespan or cancer risk is genuinely complicated — aggressively pushing telomerase-style effects is something the cancer-biology literature treats with caution, not enthusiasm.

The cognitive paper carries the same limitations: small, single-group or modestly controlled, single-team. None of this means the effect is fake. It means the evidence is at the "intriguing preliminary signal" stage — the level where more research is warranted, not the level where a clinic should be charging you to reverse your biological age.

Cost and burden are not trivial

The longevity protocol in the study was 60 sessions over three months — five days a week, each session running well over an hour including compression and decompression. Replicating that at a private clinic runs into the thousands to tens of thousands of dollars, since anti-aging HBOT is not covered by insurance (it's an off-label, non-approved use). That's a large commitment of money and time for an effect supported by one uncontrolled study. For how this slots into the broader spend question, see our longevity clinic cost breakdown and our graded take on whether longevity clinics are worth it.

Safety: real but generally manageable

HBOT is not risk-free. The well-documented adverse effects are mostly pressure- and oxygen-related: middle-ear barotrauma (the most common), sinus squeeze, temporary nearsightedness that usually reverses, claustrophobia, and — rarely — oxygen-toxicity seizures and pulmonary effects at the upper end of dosing¹. In medically supervised settings for approved indications, serious events are uncommon. The relevant caution for longevity use isn't that HBOT is dangerous in trained hands — it's that you'd be accepting real procedural risk, real cost, and real time for an unproven anti-aging benefit. People with certain lung conditions, recent ear surgery, or specific cardiac issues need screening first. This is a medical procedure, not a spa add-on.

How it compares to better-supported levers

The honest comparison is what stings for HBOT. The cellular markers it claims to move — telomere attrition and senescence — are real hallmarks of aging³, and clearing senescent cells does extend healthy lifespan in mice⁵. But the interventions with the strongest human track record for healthspan are far cheaper and better evidenced: resistance training, cardiovascular fitness, sleep, and nutrition. HBOT asks you to pay a great deal for a single-study signal, while the highest-grade healthspan levers cost little and are backed by large bodies of evidence. We rank the supplement side of that ledger in best longevity supplements, rated by evidence, and the diagnostic side in longevity biomarker panels.

The grade

The bottom line

HBOT for aging rests on one genuinely interesting, genuinely fragile finding: a small, uncontrolled, unreplicated Israeli trial reporting longer telomeres and fewer senescent cells after 60 sessions. That's a reason to keep studying it — not a reason to treat it as a proven anti-aging therapy or to spend thousands chasing it. The mechanisms HBOT is approved for are real; the longevity claim is at the "promising signal, needs replication" stage, with telomere lengthening itself being a double-edged marker rather than a clean win. If you're drawn to it, go in clear-eyed: real cost, real procedural risk, and a single uncontrolled study behind the headline. For where interventions like this fit alongside programs with real clinical oversight, see our graded best longevity clinics hub, and compare HBOT's thin human case to a cheaper, better-mechanism neighbor in spermidine for longevity.